Intelligence Feed event · Policy · 2026-10-04

    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Trial

    Question

    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Trial

    Direct answer

    Genmab published clinical efficacy metrics from the Phase 2 RAINFOL-01 trial evaluating Rinatabart Sesutecan (Rina-S) in platinum-resistant ovarian cancer patients. The therapy achieved a 45.9% objective response rate, 12.1 months median duration of response, and 9.5 months median progression-free survival, demonstrating consistent anti-tumor activity in difficult-to-treat cohorts.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-response-rate-in-phase-2-ovarian-cancer-trial-606469

    POLICY
    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Trial
    Genmab published clinical efficacy metrics from the Phase 2 RAINFOL-01 trial evaluating Rinatabart Sesutecan (Rina-S) in platinum-resistant ovarian cancer patients. The therapy achieved a 45.9% objective response rate, 12.1 months median duration of response, and 9.5 months median progression-free survival, demonstrating consistent anti-tumor activity in difficult-to-treat cohorts.
    GMAB
    Impact
    71
    OCT 4
    SIG
    90%
    GMAB
    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Trial
    Genmab published clinical efficacy metrics from the Phase 2 RAINFOL-01 trial evaluating Rinatabart Sesutecan (Rina-S) in platinum-resistant ovarian cancer patients. The therapy achieved a 45.9% objective response rate, 12.1 months median duration of response, and 9.5 months median progression-free survival, demonstrating consistent anti-tumor activity in difficult-to-treat cohorts.
    → A 45.9% objective response rate in platinum-resistant ovarian cancer strengthens Genmab antibody-drug conjugate pipeline commercialization probability.
    Impact
    Genmab published clinical efficacy metrics from the Phase 2 RAINFOL-01 trial evaluating Rinatabart Sesutecan (Rina-S) in platinum-resistant ovarian cancer patients. The therapy achieved a 45.9% objective response rate, 12.1 months median duration of response, and 9.5 months median progression-free survival, demonstrating consistent anti-tumor activity in difficult-to-treat cohorts.
    Affected
    GMAB
    Transmission
    A 45.9% objective response rate in platinum-resistant ovarian cancer strengthens Genmab antibody-drug conjugate pipeline commercialization probability.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABpipeline net present value repricing on Phase 2 oncology efficacy dataUp1-5dPhase 2 RAINFOL-01 trial of Rina-S showed 45.9% ORR, 12.1 months median DOR, and 9.5 months median PFS.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month